AI assistant
NYRADA INC. — Capital/Financing Update 2021
Dec 9, 2021
65469_rns_2021-12-09_4a5a4a03-1501-4494-b4dd-592d5c05bfaf.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [596 x 114] intentionally omitted <==
Release of Securities from Escrow
Sydney, 10 December 2021: Nyrada Inc (ASX: NYR) wishes to advise in accordance with Listing Rule 3.10A that the following restricted securities will be released from escrow on 16 January 2022.
| ASX Code | Number | To be listed / Unlisted |
Class |
|---|---|---|---|
| NYRAB | 33,105,853 | To be listed(1) | Chess DepositaryInterests(Restricted) |
| NYRAC | 8,000,000 | Unlisted | Warrants expiring30-Jun-2024(Restricted) |
| NYRAE | 18,000,000 | Unlisted | Performance Shares(Restricted) |
| NYRAG | 800,000 | Unlisted | Option expiring16-Jan-2023(Restricted) |
| NYRAH | 28,800,000 | Unlisted | Option expiring var dates (Restricted) ex var prices |
(1) The Company will apply for their quotation no later than 5 business days after the end of the escrow period by lodging an Appendix 2A as per Listing Rule 2.8.5.
About Nyrada Inc
Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, US, and the liability of its stockholders is limited.
www.nyrada.com
The release of this announcement has been authorised by Mr David Franks, Company Secretary, on behalf of the Nyrada Inc Board of Directors
| Investor & Corporate Enquiries: | Company Secretary: |
|---|---|
| Laura Vize | David Franks |
| Investor Relations Manager | T: 02 8072 1400 |
| T: 0417 026 056 | E:[email protected] |
| E:[email protected] |
Page 1
Nyrada Inc. Level 3, 828 Pacific Highway, Gordon NSW 2072
ARBN 625 401 818
==> picture [596 x 114] intentionally omitted <==
Media Enquiries:
Catherine Strong Citadel-MAGNUS T: 02 8234 0111
Forward-Looking Statements
This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections, and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance, or achievements to differ materially from those expressed or implied by the forward-looking statement.
Page 2
Nyrada Inc. Level 3, 828 Pacific Highway, Gordon NSW 2072
ARBN 625 401 818